FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+25.98%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$1.67B
AUM Growth
+$1.67B
(+21%)
Cap. Flow
+$72.6M
Cap. Flow
% of AUM
4.33%
Top 10 Holdings %
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5
Top Buys
| 1 |
Disc Medicine
IRON
|
$29.1M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
$24.4M |
| 3 |
NewAmsterdam Pharma
NAMS
|
$18.2M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$16.6M |
| 5 |
BridgeBio Pharma
BBIO
|
$14.1M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$11.6M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$11.6M |
| 3 |
Cogent Biosciences
COGT
|
$7.79M |
| 4 |
Avidity Biosciences
RNA
|
$7.68M |
| 5 |
Replimune Group
REPL
|
$6.97M |
Sector Composition
| 1 | Healthcare | 99.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
HilleVax
HLVX
$105M
| $168M | 10.04% | 9,781,472 | – | – |
|
|
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $167M | 9.97% | 4,345,559 | – | – |
|
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $145M | 8.65% | 10,109,279 +1,702,127 | +20% | +$24.4M |
|
|
4
NewAmsterdam Pharma
NAMS
$2.71B
| $129M | 7.72% | 10,871,803 +1,530,252 | +16% | +$18.2M |
|
5
Krystal Biotech
KRYS
$4.27B
| $116M | 6.94% | 990,260 +44,853 | +5% | +$5.27M |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $113M | 6.74% | 4,360,107 +500,000 | +13% | +$12.9M |
|
7
Arcutis Biotherapeutics
ARQT
$1.86B
| $82.8M | 4.94% | 8,684,232 | – | – |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $77.6M | 4.64% | 3,708,838 | – | – |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| $62.2M | 3.72% | 2,944,349 | – | – |
|
|
10
Vaxcyte
PCVX
$4B
| $58.2M | 3.47% | 1,164,405 -233,000 | -17% | -$11.6M |
|
11
Rhythm Pharmaceuticals
RYTM
$6.85B
| $35.7M | 2.13% | 2,167,222 +2,483 | +0.1% | +$40.9K |
|
|
12
BridgeBio Pharma
BBIO
$9.89B
| $34.2M | 2.04% | 1,988,876 +817,226 | +70% | +$14.1M |
|
13
Tarsus Pharmaceuticals
TARS
$2.47B
| $32.3M | 1.93% | 1,787,527 | – | – |
|
|
ALPN
14
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $30.7M | 1.83% | 2,985,757 | – | – |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $29.1M | 1.74% | 3,238,859 | – | – |
|
|
16
Disc Medicine
IRON
$2.07B
| $29.1M | 1.74% | +655,000 | New | +$29.1M |
|
17
Crinetics Pharmaceuticals
CRNX
$2.92B
| $25.5M | 1.52% | 1,414,823 | – | – |
|
18
Revolution Medicines
RVMD
$7.1B
| $22.9M | 1.37% | 854,484 | – | – |
|
|
THRX
19
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $21M | 1.25% | 2,248,194 | – | – |
|
20
Acadia Pharmaceuticals
ACAD
$4.38B
| $20.5M | 1.23% | 857,338 | – | – |
|
21
Merus
MRUS
$4.98B
| $19.7M | 1.17% | 746,479 | – | – |
|
22
AnaptysBio
ANAB
$569M
| $18.3M | 1.09% | 899,700 | – | – |
|
|
23
Cogent Biosciences
COGT
$1.69B
| $17.8M | 1.06% | 1,501,383 -657,771 | -30% | -$7.79M |
|
24
Tyra Biosciences
TYRA
$675M
| $17.5M | 1.05% | 1,028,013 -393,297 | -28% | -$6.7M |
|
|
JBIO
25
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $17.1M | 1.02% | 994,858 +656,748 | +194% | +$11.3M |
|